<DOC>
	<DOCNO>NCT00428025</DOCNO>
	<brief_summary>Inflammation pancreas ( pancreatitis ) uncommon potentially serious complication endoscopic retrograde cholangiopancreatography ( ERCP ) , specialize endoscopic examination ducts drain liver pancreas . Although many different strategy try studied attempt reduce risk , show make significant difference . Those either expensive , difficult administer , . Diclofenac , anti-inflammatory medication often use treat arthritis , show potential decrease risk post-ERCP pancreatitis . It give procedure patient risk complication , side effect . This study randomize people study placebo active medication , determine Diclofenac reduces incidence pancreatitis .</brief_summary>
	<brief_title>Diclofenac Prevention Post-ERCP Pancreatitis Higher Risk Patients</brief_title>
	<detailed_description>Hypothesis : Diclofenac , administer immediately post ERCP patient higher risk develop post-ERCP pancreatitis , significantly reduce incidence complication . Intervention : All patient undergo ERCP exclusion criterion approach participation prior procedure . At end procedure , prior transfer endoscopy suite , within 15 minute end procedure , patient meet inclusion criterion , study suppository administer . The suppository prepare study pharmacist accord randomization list prepared independent biostatistician . They randomize use permuted block design , block 20 . The placebo inert , identical study medication , 100 mg diclofenac rectal suppository . The code broken enrolment patient complete . Patients , endoscopists , nurse , principal investigator blind randomization code . Outcomes : Post-ERCP acute pancreatitis primary outcome . Consensus definition new typical ( epigastric/retroperitoneal ) pain combine elevation serum lipase amylase &gt; 3 time upper limit normal . Pain assess history physical exam attend gastroenterologist morning procedure , documentation chart research form presence absence pain . Serum amylase measure morning procedure , 7 10 ( approximately 18 hour post procedure ) . Most patient inpatient outpatient include assessed clinical exam blood chemistry analysis follow morning . Patients contact one week procedure ensure episode abdominal pain bleeding miss . Statistics Power Calculation A two side Fisher 's Exact Test use compare proportion patient develop post-ERCP pancreatitis group ( placebo vs. active drug ) . In population select , estimate risk pancreatitis 15 % . To demonstrate decrease 5 % , 141 patient require group , 80 % power alpha error 0.05 . Secondary outcome include severity pancreatitis , hyperamylasemia , length stay , mortality . Safety data regard renal function GI bleeding also collect .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>These chosen base review major study evaluate risk factor postERCP pancreatitis . Any following factor place patient high risk ( &gt; 10 % ) post ERCP pancreatitis : Patient characteristic : Prior history postERCP pancreatitis , prior history acute pancreatitis , suspect Sphincter Oddi dysfunction , normal bilirubin ; Procedure relate factor : Moderate ( 615 attempt ) difficult ( &gt; 15 attempt ) bile duct cannulation , balloon dilation biliary sphincter , precut papillotomy , pancreatic sphincterotomy . Ongoing acute chronic pancreatitis ; Previous biliary sphincterotomy ; Contraindications nonsteroidal antiinflammatory medication ( allergy , reduce renal function , recent upper gastrointestinal bleeding ) ; Ingestion NSAID ( nonsteroidal antiinflammatory drug ) previous 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>pancreatitis</keyword>
</DOC>